Top

Published in:

01-04-2015 | Original Communication

Clinical and molecular aspects of 30 patients with late-onset Pompe disease (LOPD): unusual features and response to treatment

Authors: Federica Montagnese, E. Barca, O. Musumeci, S. Mondello, A. Migliorato, A. Ciranni, C. Rodolico, P. De Filippi, C. Danesino, A. Toscano

Published in: Journal of Neurology | Issue 4/2015

Abstract

Pompe disease is a rare metabolic disorder, due to mutations in the gene encoding acid alpha-glucosidase (GAA), of which infantile and late-onset forms may occur. Aim of the work was to analyze clinical and laboratory data of a cohort of late-onset Pompe disease (LOPD) patients, collected during the last 15 years and to point out unusual phenotypic/genotypic features as well as enzyme replacement therapy (ERT) responses. We diagnosed 30 LOPD patients; at follow-up, they underwent motor, respiratory, cardiac and muscle MRI evaluations. Motor performances were tested by Walton Gardner-Medwin, GSGC and 6MWT tests. Respiratory function was assessed as FVC % in upright/supine position. LOPD presentations were represented by presymptomatic hyperCKemia (37 %), proximal/axial muscle weakness (53 %) and respiratory impairment (10 %). Median diagnostic delay was 8.6 years (±8.8). Atypical features were observed in 4 patients: marked distal muscle weakness and severe hearing loss at onset, as well as leukoencephalopathy and mesial temporal sclerosis during the disease course. By GAA sequence analysis, two causing mutations were detected in 22/30 patients, only one in the remaining 8 subjects. Overall, 29/30 patients harbored the common c.−32−13T>G mutation (2 were homozygous). Two new DNA variations were discovered (c.2395C>G, c.1771C>T). 14 patients received ERT for up to 60 months. Our study confirms LOPD clinical and genetic heterogeneity: atypical features may contribute to expand the clinical phenotype highlighting its multi-systemic nature. A timely diagnosis could allow early ERT start. An accurate follow-up is recommended to evaluate treatment responses.

Kishnani PS, Amartino HM, Lindberg C, Miller TM, Wilson A, Keutzer J, On behalf of the Pompe Registry Boards of Advisors (2013) Timing of diagnosis of patients with Pompe disease: data from the Pompe Registry. Am J Med Genet Part A 161A:2431–2443PubMed

Kroos MA, van der Kraan M, van Diggelen OP, Kleijer WJ, Reuser AJ, van den BooGAArd MJ, Ausems MG, van Ploos Amstel HK, Poenaru L, Nicolino M (1995) Glycogen storage disease type II: frequency of three common mutant alleles and their associated clinical phenotypes studied in 121 patients. J Med Genet 32:836–837PubMedCentralCrossRefPubMed

Reuser AJJ, Verheijen FW, Kroos MA et al (1995) Glycogenosis type II (acid maltase deficiency). Muscle Nerve 3:S61CrossRefPubMed

Lim JA, Li L, Raben N (2014) Pompe disease: from pathophysiology to therapy and back again. Front Aging Neurosci. 23(6):177

Van der Ploeg AT, Reuser AJ (2008) Pompe’s disease. Lancet 372:1342–1353CrossRefPubMed

Laforet P, Nicolino M, Eymard PB, Puech JP, Caillaud C, Poenaru L, Fardeau M (2000) Juvenile and adult-onset acid maltase deficiency in France: genotype phenotype correlation. Neurology 55:1122–1128CrossRefPubMed

Montalvo AL, Bembi B, Donnarumma M, Filocamo M, Parenti G, Rossi M, Merlini L, Buratti E, De Filippi P, Dardis A et al (2006) Mutation profile of the GAA gene in 40 Italian patients with late onset glycogen storage disease type II. Hum Mutat 27:999–1006CrossRefPubMed

Herzog A, Hartung R, Reuser A, Hermanns P, Runz H, Karabul N, Gökce S, Pohlenz J, Kampmann C, Lampe C, Beck M, Mengel E (2012) A cross-sectional single-centre study on the spectrum of Pompe disease, German patients: molecular analysis of the GAA gene, manifestation and genotype-phenotype correlations. Orphanet J Rare Dis 7:35PubMedCentralCrossRefPubMed

Joshi PR, Gläser D, Schmidt S, Vorgerd M, Winterholler M, Eger K, Zierz S, Deschauer M (2008) Molecular diagnosis of German patients with late-onset glycogen storage disease type II. J Inherit Metab Dis 31(Suppl 2):S261–S265CrossRefPubMed

10.

Kroos M, Pomponio RJ, van Vliet L, Palmer RE, Phipps M, Van der Helm R, Halley D, Reuser AJ (2008) GAA Database Consortium. Update of the Pompe disease mutation database with 107 sequence variants and a format for severity rating. Hum Mutat 29(6):E13–E26CrossRefPubMed

11.

Kroos M, Hoogeveen-Westerveld M, Van der Ploeg A, Reuser AJ (2012) The genotype phenotype correlation in Pompe disease. Am J Med Genet C Semin Med Genet 160C(1):59–68CrossRefPubMed

12.

Toscano A, Montagnese F, Musumeci O (2013) Early is better? A new algorithm for early diagnosis in late onset Pompe disease (LOPD). Acta Myol 32(2):78–81PubMedCentralPubMed

13.

Carlier RY, Laforet P, Wary C, Mompoint D, Laloui K, Pellegrini N, Annane D, Carlier PG, Orlikowski D (2011) Whole-body muscle MRI in 20 patients suffering from late onset Pompe disease: involvement patterns. Neuromuscul Disord 21(11):791–799CrossRefPubMed

14.

Gaeta M, Barca E, Ruggeri P, Minutoli F, Rodolico C, Mazziotti S, Milardi D, Musumeci O, Toscano A (2013) Late-onset Pompe disease (LOPD): correlations between respiratory muscles CT and MRI features and pulmonary function. Mol Genet Metab 110(3):290–296CrossRefPubMed

15.

Van der Ploeg AT, Clemens PR, Corzo D, Escolar DM, Florence J, Groeneveld GJ, Herson S, Kishnani PS, Laforet P, Lake SL, Lange DJ, Leshner RT, Mayhew JE, Morgan C, Nozaki K, Park DJ, Pestronk A, Rosenbloom B, Skrinar A, van Capelle CI, van der Beek NA, Wasserstein M, Zivkovic SA (2010) A randomized study of alglucosidase alfa in late-onset Pompe’s disease. N Engl J Med 362(15):1396–1406CrossRefPubMed

16.

Van der Ploeg AT, Barohn R, Carlson L, Charrow J, Clemens PR, Hopkin RJ, Kishnani PS, Laforêt P, Morgan C, Nations S, Pestronk A, Plotkin H, Rosenbloom BE, Sims KB, Tsao E (2012) Open-label extension study following the late-onset treatment study (LOTS) of alglucosidase alfa. Mol Genet Metab 107(3):456–461CrossRefPubMed

17.

Strothotte S, Strigl-Pill N, Grunert B, Kornblum C, Eger K, Wessig C, Deschauer M, Breunig F, Glocker FX, Vielhaber S, Brejova A, Hilz M, Reiners K, Müller-Felber W, Mengel E, Spranger M, Schoser B (2010) Enzyme replacement therapy with alglucosidase alfa in 44 patients with late-onset glycogen storage disease type 2: 12-month results of an observational clinical trial. J Neurol 257(1):91–97CrossRefPubMed

18.

Angelini C, Semplicini C, Ravaglia S, Bembi B, Servidei S, Pegoraro E, Moggio M, Filosto M, Sette E, Crescimanno G, Tonin P, Parini R, Morandi L, Marrosu G, Greco G, Musumeci O, Di Iorio G, Siciliano G, Donati MA, Carubbi F, Ermani M, Mongini T, Toscano A, Italian GSDII Group (2012) Observational clinical study in juvenile-adult glycogenosis type 2 patients undergoing enzyme replacement therapy for up to 4 years. J Neurol 259(5):952–958CrossRefPubMed

19.

Toscano A, Schoser B (2013) Enzyme replacement therapy in late-onset Pompe disease: a systematic literature review. J Neurol 260(4):951–959CrossRefPubMed

20.

Cupler EJ, Berger KI, Leshner RT, Wolfe GI, Han JJ, Barohn RJ, Kissel JT (2012) AANEM consensus committee on late-onset Pompe disease. Consensus treatment recommendations for late-onset Pompe disease. Muscle Nerve 45(3):319–323PubMedCentralCrossRefPubMed

21.

Gabellini D, D’Antona G, Moggio M, Prelle A, Zecca C, Adami R, Angeletti B, Ciscato P, Pellegrino MA, Bottinelli R, Green MR, Tupler R (2006) Facioscapulohumeral muscular dystrophy in mice overexpressing FRG1. Nature 439:973–977PubMed

22.

Remiche G, Ronchi D, Magri F, Lamperti C, Bordoni A, Moggio M, Bresolin N, Comi GP (2014) Extended phenotype description and new molecular findings in late onset glycogen storage disease type II: a northern Italy population study and review of the literature. J Neurol 261(1):83–97CrossRefPubMed

23.

Van der Beek NA, de Vries JM, Hagemans ML, Hop WC, Kroos MA, Wokke JH, de Visser M, van Engelen BG, Kuks JB, van der Kooi AJ, Notermans NC, Faber KG, Verschuuren JJ, Reuser AJ, van der Ploeg AT, van Doorn PA (2012) Clinical features and predictors for disease natural progression in adults with Pompe disease: a nationwide prospective observational study. Orphanet J Rare Dis. 12(7):88CrossRef

24.

Müller-Felber W, Horvath R, Gempel K, Podskarbi T, Shin Y, Pongratz D, Walter MC, Baethmann M, Schlotter-Weigel B, Lochmüller H, Schoser B (2007) Late onset Pompe disease: clinical and neurophysiological spectrum of 38 patients including long-term follow-up in 18 patients. Neuromuscul Disord 17(9–10):698–706CrossRefPubMed

25.

de Vries JM, van der Beek NA, Hop WC, Karstens FP, Wokke JH, de Visser M, van Engelen BG, Kuks JB, van der Kooi AJ, Notermans NC, Faber CG, Verschuuren JJ, Kruijshaar ME, Reuser AJ, van Doorn PA, van der Ploeg AT (2012) Effect of enzyme therapy and prognostic factors in 69 adults with Pompe disease: an open-label single-center study. Orphanet J Rare Dis 7:73PubMedCentralCrossRefPubMed

26.

Tsujino S, Huie M, Kanazawa N, Sugie H, Goto Y, Kawai M, Nonaka I, Hirschhorn R, Sakuragawa N (2000) Frequent mutations in Japanese patients with acid maltase deficiency. Neuromuscul Disord 10(8):599–603CrossRefPubMed

27.

Pittis MG, Filocamo M (2007) Molecular genetics of late onset glycogen storage disease II in Italy. Acta Myol 26(1):67–71PubMedCentralPubMed

28.

Dardis A, Zanin I, Zampieri S, Stuani C, Pianta A, Romanello M, Baralle FE, Bembi B, Buratti E (2014) Functional characterization of the common c.−32−13T>G mutation of GAA gene: identification of potential therapeutic agents. Nucleic Acids Res 42(2):1291–1302PubMedCentralCrossRefPubMed

29.

Huie ML, Chen AS, Tsujino S, Shanske S, DiMauro S, Engel AG, Hirschhorn R (1994) Aberrant splicing in adult onset glycogen storage disease type II (GSDII): molecular identification of an IVS1 (−13T→G) mutation in a majority of patients and a novel IVS10 (+1GT→CT) mutation. Hum Mol Genet 3(12):2231–2236CrossRefPubMed

30.

Martini C, Ciana G, Benettoni A et al (2001) Intractable fever and cortical neuronal glycogen storage in glycogenosis type 2. Neurology 57:906–908CrossRefPubMed

31.

Martin JJ, de Barsy T, Van Hoof F et al (1973) Pompe’s disease: an inborn lysosomal disorder with storage of glycogen. Acta Neuropathol 23:229–244CrossRefPubMed

32.

Mancall EL, Aponte GE, Berry RG (1965) Pompe’s disease (diffuse glycogenosis) with neuronal storage. J Neuropathol Exp Neurol 24:85–96CrossRefPubMed

33.

Papadimas G, Terzis G, Papadopoulos C, Areovimata A, Spengos K, Kavouras S, Manta P (2012) Bone density in patients with late onset Pompe disease. Int J Endocrinol Metab 10(4):599–603PubMedCentralCrossRefPubMed

34.

Sacconi S, Bocquet JD, Chanalet S, Tanant V, Salviati L, Desnuelle C (2010) Abnormalities of cerebral arteries are frequent in patients with late-onset Pompe disease. J Neurol 257(10):1730–1733CrossRefPubMed

35.

Oktenli C (2000) Renal magnesium wasting, hypomagnesemic hypocalcemia, hypocalciuria and osteopenia in a patient withglycogenosis type II. Am J Nephrol 20(5):412–417CrossRefPubMed

36.

Bernstein DL, Bialer MG, Mehta L, Desnick RJ (2010) Pompe disease: dramatic improvement in gastrointestinal function following enzyme replacement therapy. A report of three later-onset patients. Mol Genet Metab 101(2–3):130–133CrossRefPubMed

37.

Karabul N, Skudlarek A, Berndt J, Kornblum C, Kley RA, Wenninger S, Tiling N, Mengel E, Plöckinger U, Vorgerd M, Deschauer M, Schoser B, Hanisch F (2014) Urge incontinence and gastrointestinal symptoms in adult patients with Pompe disease: a cross-sectional survey. JIMD Rep 17:53–61PubMedCentralCrossRefPubMed

38.

Musumeci O, Catalano N, Barca E, Ravaglia S, Fiumara A, Gangemi G, Rodolico C, Sorge G, Vita G, Galletti F, Toscano A (2012) Auditory system involvement in late onset Pompe disease: a study of 20 Italian patients. Mol Genet Metab 107(3):480–484CrossRefPubMed

39.

Van der Beek NA, Verschuure H, Reuser AJ, van der Ploeg AT, van Doorn PA, Poublon RM (2012) Hearing in adults with Pompe disease. J Inherit Metab Dis 35(2):335–341PubMedCentralCrossRefPubMed

40.

Remiche G, Herbaut AG, Ronchi D, Lamperti C, Magri F, Moggio M, Bresolin N, Comi GP (2012) Incontinence in late-onset Pompe disease: an underdiagnosed treatable condition. Eur Neurol 68(2):75–78CrossRefPubMed

41.

Hagemans ML, Stigter RL, van Capelle CI, van der Beek NA, Winkel LP, van Vliet L, Hop WC, Reuser AJ, Beishuizen A, van der Ploeg AT (2010) PAS-positive lymphocyte vacuoles can be used as diagnostic screening test for Pompe disease. J Inherit Metab Dis 33(2):133–139PubMedCentralCrossRefPubMed

42.

Ravaglia S, Repetto A, De Filippi P, Danesino C (2007) Ptosis as a feature of late-onset glycogenosis type II. Neurology. 69(1):116CrossRefPubMed

43.

Hobson-Webb LD, Jones HN, Kishnani PS (2013) Oropharyngeal dysphagia may occur in late-onset Pompe disease, implicating bulbar muscle involvement. Neuromuscul Disord 23(4):319–322CrossRefPubMed

44.

Hanisch F, Rahne T, Plontke SK (2013) Prevalence of hearing loss in patients with late-onset Pompe disease: audiological and otological consequences. Int J Audiol 52(12):816–823CrossRefPubMed

45.

Borroni B, Cotelli MS, Premi E et al (2013) The brain in late-onset glycogenosis II: a structural and functional MRI study. J Inherit Metab Dis 36:989–995CrossRefPubMed

46.

Tsai MH, Pardoe HR, Perchyonok Y, Fitt GJ, Scheffer IE, Jackson GD, Berkovic SF (2013) Etiology of hippocampal sclerosis: evidence for a predisposing familial morphologic anomaly. Neurology 81(2):144–149PubMedCentralCrossRefPubMed

47.

Benbadis SR, Wallace J, Reed Murtagh F (2002) MRI evidence of mesial temporal sclerosis in subjects without seizures. Seizure. 11(5):340–343CrossRefPubMed

48.

Kumar R, Sachdev PS, Price JL, Rosenman S, Christensen H (2008) Incidental brain MRI abnormalities in 60- to 64-year-old community-dwelling individuals: data from the Personality and Total Health Through Life study. Acta Neuropsychiatr. 20(2):87–90CrossRefPubMed

49.

Hundsberger T, Rösler KM, Findling O (2014) Cessation and resuming of alglucosidase alfa in Pompe disease: a retrospective analysis. J Neurol. 261(9):1684–1690CrossRefPubMed

50.

Anderson LJ, Henley W, Wyatt KM, Nikolaou V, Waldek S, Hughes DA, Lachmann RH, Logan S (2014) Effectiveness of enzyme replacement therapy in adults with late-onset Pompe disease: results from the NCS-LSD cohort study. J Inherit Metab Dis. 37(6):945–952CrossRefPubMed

51.

Güngör D, Kruijshaar ME, Plug I, D’Agostino RB, Hagemans ML, van Doorn PA, Reuser AJ, van der Ploeg AT (2013) Impact of enzyme replacement therapy on survival in adults with Pompe disease: results from a prospective international observational study. Orphanet J Rare Dis. 27(8):49CrossRef

52.

Orlikowski D, Pellegrini N, Prigent H, Laforêt P, Carlier R, Carlier P, Eymard B, Lofaso F, Annane D (2011) Recombinant human acid alpha-glucosidase (rhGAA) in adult patients with severe respiratory failure due to Pompe disease. Neuromuscul Disord 21(7):477–482CrossRefPubMed

53.

Vianello A, Semplicini C, Paladini L, Concas A, Ravaglia S, Servidei S, Toscano A, Mongini T, Angelini C, Pegoraro E (2013) Enzyme replacement therapy improves respiratory outcomes in patients with late-onset type II glycogenosis and high ventilator dependency. Lung 191(5):537–544CrossRefPubMed

54.

Furusawa Y, Mori-Yoshimura M, Yamamoto T, Sakamoto C, Wakita M, Kobayashi Y, Fukumoto Y, Oya Y, Fukuda T, Sugie H, Hayashi YK, Nishino I, Nonaka I, Murata M (2012) Effects of enzyme replacement therapy on five patients with advanced late-onset glycogen storage disease type II: a 2-year follow-up study. J Inherit Metab Dis 35(2):301–310CrossRefPubMed

55.

Schneider I, Hanisch F, Müller T, Schmidt B, Zierz S (2013) Respiratory function in late-onset Pompe disease patients receiving long-term enzyme replacement therapy for more than 48 months. Wien Med Wochenschr 163(1–2):40–44CrossRefPubMed

Title: Clinical and molecular aspects of 30 patients with late-onset Pompe disease (LOPD): unusual features and response to treatment
Authors: Federica Montagnese
E. Barca
O. Musumeci
S. Mondello
A. Migliorato
A. Ciranni
C. Rodolico
P. De Filippi
C. Danesino
A. Toscano
Publication date: 01-04-2015
Publisher: Springer Berlin Heidelberg
Published in: Journal of Neurology / Issue 4/2015
Print ISSN: 0340-5354
Electronic ISSN: 1432-1459
DOI: https://doi.org/10.1007/s00415-015-7664-0

At a glance: The STEP trials

Springer Medicine

Clinical and molecular aspects of 30 patients with late-onset Pompe disease (LOPD): unusual features and response to treatment

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2015

A novel autosomal dominant leukodystrophy with specific MRI pattern

Hamsi scoring in the prediction of unfavorable outcomes from tuberculous meningitis: results of Haydarpasa-II study

Early diagnosis of cardiac involvement in idiopathic inflammatory myopathy by cardiac magnetic resonance tomography

Two-year outcome of thymectomy in non-thymomatous late-onset myasthenia gravis

Clinical and experimental studies of potentially pathogenic brain-directed autoantibodies: current knowledge and future directions

Accepting or declining non-invasive ventilation or gastrostomy in amyotrophic lateral sclerosis: patients’ perspectives